^
Association details:
| Biomarker: | CDK12 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
Excerpt:
...Human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with metastatic or locally advanced disease, which is unresectable (or the patient is not a candidate for resection) Patients must have documented evidence from Myriad central tumor testing that...do have a deleterious or suspected deleterious mutation in at least 1 of the following 13 HRR genes: ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L. (Module 9 HRRm).
Trial ID:
